Editorial: Case reports in cardio-oncology: 2022.

Autor: Ewer MS; MD Anderson Department of Cardiology, Internal Medicine Division, The University of Texas, Houston, TX, United States., Yusuf SW; MD Anderson Department of Cardiology, Internal Medicine Division, The University of Texas, Houston, TX, United States., Asmis R; Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, United States., Abe JI; MD Anderson Department of Cardiology, Internal Medicine Division, The University of Texas, Houston, TX, United States.

Publikováno v: Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2023 Jul 13; Vol. 10, pp. 1235015. Date of Electronic Publication: 2023 Jul 13 (Print Publication: 2023).

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.

Autor: de Azambuja E; Institut Jules Bordet and L'Université Libre de Bruxelles (U.L.B), Brussels, Belgium. Electronic address: evandro.azambuja@bordet.be., Agostinetto E; Institut Jules Bordet and L'Université Libre de Bruxelles (U.L.B), Brussels, Belgium., Procter M; Frontier Science, Kincraig, Kingussie, UK., Eiger D; F.Hoffmann-La Roche Ltd, Basel, Switzerland., Pondé N; Clinical Oncology Department, AC Camargo Cancer Center, São Paulo, Brazil., Guillaume S; Institut Jules Bordet and L'Université Libre de Bruxelles (U.L.B), Brussels, Belgium., Parlier D; Institut Jules Bordet and L'Université Libre de Bruxelles (U.L.B), Brussels, Belgium., Lambertini M; Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova, Genova, Italy., Desmet A; Institut Jules Bordet and L'Université Libre de Bruxelles (U.L.B), Brussels, Belgium., Caballero C; Breast International Group, Brussels, Belgium., Aguila C; F.Hoffmann-La Roche Ltd, Basel, Switzerland., Jerusalem G; CHU Liege and Liege University, Liege, Belgium., Walshe JM; Cancer Trials Ireland, St Vincent's University Hospital, Dublin, Ireland., Frank E; Dana-Farber Cancer Institute, Boston, USA., Bines J; Instituto Nacional de Cancer, INCA, Rio de Janeiro, Brazil., Loibl S; German Breast Group, Neu-Isenburg, Germany., Piccart-Gebhart M; Institut Jules Bordet and L'Université Libre de Bruxelles (U.L.B), Brussels, Belgium., Ewer MS; University of Texas, MD Anderson Cancer Center, Houston., Dent S; Duke Cancer Institute, Duke University, Durham, USA., Plummer C; Department of Cardiology, Freeman Hospital, Newcastle upon Tyne, UK., Suter T; Department of Cardiology, Cardio-Oncology, Bern University Hospital, Bern, Switzerland.

Publikováno v: ESMO open [ESMO Open] 2023 Feb; Vol. 8 (1), pp. 100772. Date of Electronic Publication: 2023 Jan 19.

Could Some Reports of Trastuzumab Cardiotoxicity Be a Surveillance Artifact?

Autor: Ewer MS; Michael S. Ewer, MD, JD, PhD, and Sandra M. Swain, MD, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX; and Georgetown Lombardi Comprehensive Cancer Center and MedStar Health, Washington, DC., Swain SM; Michael S. Ewer, MD, JD, PhD, and Sandra M. Swain, MD, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX; and Georgetown Lombardi Comprehensive Cancer Center and MedStar Health, Washington, DC.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Dec 10; Vol. 40 (35), pp. 4158-4159. Date of Electronic Publication: 2022 Jul 25.

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer.

Autor: Dang C; Department of Medicine, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Ewer MS; Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Delaloge S; Department of Medical Oncology, Institut Gustave Roussy, 94805 Paris, France., Ferrero JM; Department of Medical Oncology, Centre Antoine Lacassagne, University Côte d'Azur, 06110 Nice, France., Colomer R; Division of Medical Oncology, Hospital Universitario La Princesa, 28006 Madrid, Spain., de la Cruz-Merino L; Department of Clinical Oncology, Hospital Universitario Virgen Macarena, 41009 Seville, Spain., Werner TL; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA., Dadswell K; Global Product Development, Roche Products Limited, Welwyn Garden City AL7 1TW, UK., Verrill M; Northern Centre for Cancer Care, Freeman Hospital, Newcastle-upon-Tyne NE7 7DN, UK., Eiger D; Product Development Oncology, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland., Sarkar S; External Business Partner, Roche Products Limited, Welwyn Garden City AL7 1TW, UK., de Haas SL; Oncology Biomarker Development, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland., Restuccia E; Product Development Oncology, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland., Swain SM; Georgetown University Medical Center, Lombardi Comprehensive Cancer Center and MedStar Health, Washington, DC 20007, USA.

Publikováno v: Cancers [Cancers (Basel)] 2022 May 24; Vol. 14 (11). Date of Electronic Publication: 2022 May 24.

Perspective on the Cardiotoxicity of Third-Generation Targeted EGFRs in the Treatment of NSCLC.

Autor: Ewer MS; Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas., Ewer SM; Division of Cardiovascular Medicine, Department of Internal Medicine, University of Wisconsis School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin.

Publikováno v: JTO clinical and research reports [JTO Clin Res Rep] 2021 Oct 13; Vol. 2 (10), pp. 100233. Date of Electronic Publication: 2021 Oct 13 (Print Publication: 2021).